Section 8: Clinical Vignettes

The following vignettes illustrate common diagnostic scenarios drawn from the evidence presented in this module. Every clinical detail is grounded in the data and recommendations discussed above.

Vignette 1: The "Treatment-Resistant Depression" That Wasn't

A 34-year-old woman presents to a new psychiatrist after being referred by her primary care provider for "treatment-resistant depression." She has experienced four major depressive episodes since age 19 and has failed adequate trials of sertraline, escitalopram, and venlafaxine. Her current episode features hypersomnia (sleeping 12-14 hours daily), increased appetite with 15-pound weight gain, leaden paralysis, and severe psychomotor retardation.

**The diagnostic clues this module addresses: **Her early age of onset (19, Red Flag 4), highly recurrent course (four episodes, Red Flag 3), antidepressant non-response (three adequate trials, Red Flag 1), and atypical depressive features (hypersomnia, hyperphagia, leaden paralysis, Section 5.1) all raise the probability of an underlying bipolar diathesis. The CANMAT framework explicitly identifies these features as "suggestive of bipolarity" (Section 2.1).

**What the evaluation should include: **The psychiatrist administers the BSDS (Section 3.4), given its superior sensitivity for Bipolar II over the MDQ. The patient endorses the narrative description with high resonance. With her husband present for collateral history (Section 4.3), he describes two distinct periods, each lasting 5-7 days over the past three years, when she "suddenly seemed like a different person": sleeping only 3-4 hours but seeming energized, talking rapidly, starting multiple home renovation projects simultaneously, and spending significantly more money than usual. The patient describes these periods as "finally feeling normal after being depressed for so long."

**The clinical reasoning: **The husband's history provides clear evidence of hypomanic episodes (decreased need for sleep with preserved energy, increased goal-directed activity, pressured speech) lasting more than 4 days. The patient's "feeling normal" description exemplifies the ego-syntonic nature of hypomania discussed in Section 1.3. This is Bipolar II disorder, not treatment-resistant unipolar depression. Her treatment plan should shift from antidepressant monotherapy (which has failed because it was treating the wrong condition) to a mood-stabilizer-first approach.

Vignette 2: Stimulant Intoxication or First Manic Episode?

A 22-year-old male college student is brought to the emergency department by campus police after being found on a campus rooftop at 3 AM, speaking rapidly about plans to launch a technology company that will "change the world." He has not slept in approximately three days, is intensely irritable when contradicted, and has been sending aggressive messages to professors demanding immediate meetings. He admits to using Adderall obtained from friends during finals week but denies other substance use. He has no prior psychiatric history, but his mother has bipolar I disorder.

**The diagnostic challenge this module addresses: **Stimulant intoxication can closely mimic acute mania (Section 5.4). The temporal relationship between substance use and symptom onset is the critical differentiator.

**What the evaluation should include: **Toxicology screening (Section 6.2) confirms amphetamine. The medical workup rules out organic contributors (TSH normal, metabolic panel unremarkable). The family history of bipolar I is a significant diagnostic anchor (Section 4.3, OR = 64 for familial aggregation).

**The clinical reasoning: **Stimulant-induced mania typically resolves within 24-48 hours of clearance (Section 5.4). The clinical plan is to observe in a safe, monitored setting after substance clearance. If symptoms persist beyond approximately one month of documented abstinence, primary bipolar I disorder should be strongly suspected, particularly given the strong family history. The dose-response data is relevant: the study finding that amphetamine doses >30 mg dextroamphetamine equivalents were associated with a 5.28-fold increased risk of mania highlights the pharmacological plausibility of stimulant-induced mania at the doses used in recreational contexts. However, methylphenidate was not associated with increased risk (Section 5.4), an important consideration for future ADHD treatment decisions if both diagnoses are confirmed.

Vignette 3: Bipolar Disorder or Borderline Personality Disorder?

A 28-year-old woman is referred by her therapist for psychiatric evaluation after several months of intense mood instability, impulsive spending, and two suicide attempts in the past year. She describes "mood swings" that her therapist suspects may represent hypomania. She endorses 9 of 13 MDQ items with a positive co-occurrence screen.

**The diagnostic challenge this module addresses: **The MDQ generates false positives at high rates in patients with BPD (Section 3.2). A positive MDQ score does not distinguish between bipolar disorder and borderline personality disorder.

**What the evaluation should include: **The evaluator should focus on the temporal architecture of the mood shifts (Section 5.3). Specific probes: "When your mood shifts, how long does the shift typically last? Hours? Days? Weeks?" "Is there usually a specific trigger, like a fight with someone close to you or a feeling of being abandoned, or do the mood changes seem to come out of nowhere?" Assessment for identity disturbance: "Between these mood shifts, do you have a stable sense of who you are and what you value, or does that feel changeable?"

**The clinical reasoning: **On detailed evaluation, the patient's "mood swings" typically last hours, not days. They are consistently triggered by interpersonal conflict, particularly perceived rejection. She describes a chronic sense of emptiness and uncertainty about her identity. Between mood episodes, she does not have a stable baseline. The specific MDQ items she endorsed, including impulsivity, sexual risk-taking, and irritability, are the items that discriminate poorly between BPD and bipolar disorder (Section 3.2). She did not endorse the "Vöhringer triad" (elevated mood, increased goal-directed activity, episodic co-occurrence) that better discriminates bipolar from BPD.

This presentation is more consistent with borderline personality disorder than bipolar disorder. The treatment plan should prioritize dialectical behavior therapy rather than mood stabilizers. Misdiagnosing this as bipolar disorder would expose her to the metabolic risks of antipsychotics and mood stabilizers without treating the underlying personality pathology.

Key Takeaways for Clinical Practice

The diagnostic delay in bipolar disorder averages 5 to 10 years

and has not improved meaningfully despite two decades of psychiatric

education. The delay is structural, driven by the fundamental

asymmetry of how patients experience the two poles of their illness:

depression drives them to seek help, while hypomania feels like

wellness and goes unreported.

Every depressed patient must be systematically screened for a

history of mania or hypomania before initiating antidepressant

therapy. All major international guidelines (CANMAT, BAP, NICE,

VA/DoD) agree that antidepressant monotherapy is contraindicated in

Bipolar I and carries significant risk in Bipolar II. This is the

single most important clinical action this module supports.

Screening instruments flag risk; they do not diagnose. The MDQ

is best for ruling out bipolar in psychiatric populations but misses

most Bipolar II cases. The RMS offers superior sensitivity with

brevity suited to primary care but was primarily validated for

Bipolar I. The BSDS captures subtle Bipolar II presentations through

narrative rather than checklists and should be added when BD-II is

specifically suspected. The HCL-32 maximizes sensitivity at the cost

of high false-positive rates. A positive screen always requires

structured clinical follow-up.

Collateral history from family members or partners is not

optional; it is strongly recommended across all major guidelines. Patient recall of past

hypomania is accurate only about 44-63% of the time. Spouses and

family members are substantially more reliable reporters of the

objective behavioral signs of hypomania, including decreased sleep

need, pressured speech, and impulsive behavior.

Interview questions should target observable behaviors, not

subjective mood states. Ask about sleep quantity and next-day

energy, specific projects started, reactions from family members, and

spending patterns. Questions about "feeling euphoric" miss more

cases than questions about "needing much less sleep but feeling

completely energized."

For therapists and non-prescribing clinicians: When a client

recently started an antidepressant and suddenly presents with rapid

speech, unusual energy, grandiosity, or severe agitation, this is

very likely the unmasking of latent bipolar disorder, not a standard

medication side effect. Coordinate an urgent psychiatric referral.

For primary care prescribers: Before writing an antidepressant

prescription for any depressed patient, check for seven clinical red

flags: antidepressant non-response, antidepressant-associated

activation, highly recurrent depression, early-onset depression

(<25), psychotic features, family history of bipolar disorder, and

postpartum mood episode. No validated threshold exists for how many

red flags are required to trigger evaluation; clinical judgment

should weigh the number, strength, and combination of factors

present. The presence of multiple red flags, particularly a

combination of early onset, family history, and antidepressant

non-response, should prompt formal bipolar evaluation before

proceeding with antidepressant monotherapy.

The minimum medical workup before initiating mood-stabilizing

treatment includes: CBC, comprehensive metabolic panel

(electrolytes, renal function, liver function), fasting

glucose/lipids, TSH, toxicology screen, and pregnancy test for women

of childbearing potential. Ordering these at the time of referral

accelerates treatment initiation.

Mixed features change everything. When a depressed patient

simultaneously exhibits manic symptoms (elevated energy, racing

thoughts, decreased sleep need, impulsive behavior), antidepressant

monotherapy becomes actively dangerous. Treatment pivots to atypical

antipsychotics or mood stabilizers. Mixed features also significantly

elevate suicide risk and require heightened monitoring.

Borderline personality disorder is the most common diagnostic

confounder. The key distinction is temporal: bipolar episodes last

days to weeks and are often autonomous; BPD mood shifts last hours

and are interpersonally triggered. MDQ positive scores do not

distinguish between the two. Identity disturbance and chronic

emptiness between mood episodes favor BPD.

PsychHQ

Clinical Vignettes & Key Takeaways